Plasmapp Co. Ltd.

Plasmapp Co. Ltd.

KKRX:405000
3,550.00
KRW
-10.00
(-0.28%)
-2,189.41EPS
15.04BMarket Cap
Plasmapp Co. Ltd.
KRX:405000
(Korea Stock Exchange)

Recent

price

3,550.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
TTM
KRW
11,642.91
6,239.52
8,240.43
6,867.13
4,461.78
2,463.9
3,404.35
Revenue per Share
-63,319.92
-21,309.99
-10,950
-9,990
-9,146.23
-1,913.18
-2,189.41
Basic EPS, GAAP
-22,814.59
-10,045.34
-17,417.08
-12,761.77
-5,146.76
-1,394.52
-2,458.72
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-29,179
5,878.14
5,288.68
3,991.88
1,736.05
1,490.65
341.61
Book Value per Share
-29,278.42
5,722.47
5,085.96
3,775.22
1,476.63
1,316.69
57.44
Tangible Book Value per Share
- -
1
2
2
2
3
4
Basic Weighted Avg Shares
2,956
6,349
13,306
12,917
10,139
8,483
12,016
Sales/Revenue/Turnover
-226.24
-167.66
-130.41
-159.26
-174.16
-89.6
-58.97
Operating Margin (%)
794
828
1,092
1,776
1,773
1,307
1,126
Depreciation Expense
-16,075
-21,682
-17,681
-18,792
-20,785
-6,587
-7,728
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-543.85
-341.53
-132.88
-145.48
-204.99
-77.65
-64.31
Profit Margin (%)
-54,603
11,250
8,179
6,656
-2,201
1,271
-1,108
Working Capital
2,000
5,225
14,616
8,202
503
955
3,025
LT Debt
-51,667
10,408
9,370
8,077
4,527
5,720
1,311
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-178.79
-215.41
-329.8
-128.57
-154.6
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
8,433
8,763
9,968
LT Borrowings
903
1,168
2,992
LT Finance Leases
52
30
33
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
4
4
Market Capitalization
22,255
27,435
15,041

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
14,144
12,443
12,735
Cash, Cash Equivalents & STI
4,067
2,193
2,541
Accounts Receivable, Net
6,161
5,936
5,545
Inventories
3,519
3,775
4,378
Total Current Liabilities
12,873
12,954
13,843
Payables & Accruals
- -
- -
- -
ST Debt
8,433
8,763
9,968
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-32.31%
26.34%
Free Cash Flow
- -
25.35%
-58.95%
Net Income, GAAP
- -
-7%
-68.31%
Sales/Revenue/Turnover
- -
36.72%
-16.34%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,077
2,575
1,585
1,902
10,139
2025
1,042
1,090
2,160
4,190
8,483
2026
2,822
2,844
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1,780
-28,529.95
-2,390
-2,148.37
-9,146.23
2025
-10,210
-321
-690.13
-336.19
-1,913.18
2026
-603.87
-605
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Plasmapp Co., Ltd. is a South Korea-based medical technology company that specializes in the development, manufacturing, and commercialization of advanced low-temperature plasma sterilization solutions and plasma bio-surface treatment systems for clinical applications. Founded in 2015 and headquartered in Daejeon, South Korea, the company serves healthcare providers across dental, orthopedic, ophthalmology, veterinary, and aesthetic surgical sectors globally. Plasmapp's core product and service portfolio comprises: low-temperature hydrogen peroxide vacuum plasma sterilizers marketed under the STERLINK brand (including STERLINK FPS, STERLINK 15sp, STERLINK mini, and STERLINK lite), which deliver rapid, low-heat instrument sterilization cycles; proprietary consumable sterilization packaging systems marketed under the Sterpack and Sterpack Plus lines, featuring direct-injection pouches and cassettes; vacuum plasma surface treatment devices marketed under the ACTILINK brand (including ACTILINK Reborn and ACTILINK Motion), designed to enhance the hydrophilicity, bio-compatibility, and osseointegration rates of dental implants, orthopedic screws, and biomaterials; and related consumables, biological indicators, chemical validation strips, and maintenance services. The company conducts business worldwide across North America, Europe, the Asia-Pacific region, Latin America, and the Middle East, supported by its overseas subsidiary, Plasmapp USA Inc. In recent developments, Plasmapp completed its public listing on the KOSDAQ market (KRX: 405000) and secured regulatory clearances, including United States Food and Drug Administration (FDA) 510(k) clearance for its STERLINK sterilization technology. The company has also expanded its global market reach by entering into long-term strategic supply, distribution, and original equipment manufacturer (OEM) partnerships with leading international dental and orthopedic implant corporations across the United States, Japan, and Europe, while broadening its research and commercial initiatives into regenerative medicine and specialized veterinary surgical care.